Europe Ready to Cash In on Cheap Copies of AbbVie Biotech Drug

By REUTERS
NYT
U.S. drugmaker AbbVie ABBV.N faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – hit the market.
Published date: August 29, 2018 at 04:32PM
Reuters
New York Times article